Validation and Feasibility of Noninvasive Oxygen Delivery Index Monitoring in Cardiac Surgery Patients
2026年8月17日 更新者:University of Minnesota
This study will establish the feasibility and preliminary validity of real-time oxygen delivery index (DO₂i) monitoring using noninvasive hemoglobin (SpHb, Masimo) and minimally invasive cardiac output (FloTrac, Edwards) in cardiac surgery patients.
研究概览
研究类型
观察性的
注册 (估计的)
150
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Sherilyn Landree
- 电话号码:(612) 282-3705
- 邮箱:landr184@umn.edu
学习地点
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55455
- University of Minnesota
-
接触:
- Sherilyn Landree
- 电话号码:612-282-3705
- 邮箱:landr184@umn.edu
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
取样方法
非概率样本
研究人群
Adults undergoing cardiac surgery
描述
Inclusion Criteria:
- Adults ≥ 18 years undergoing cardiac surgery
- Placement of pulmonary artery catheter with continuous cardiac output (CCO) as part of routine clinical care
- Placement of arterial line with FloTrac as part of routine clinical care
- Availability of ≥ 3 arterial blood gas samples at specified timepoints
Exclusion Criteria:
- Mechanical circulatory support planned or in use (IABP, Impella, ECMO)
- Patients without BOTH pulmonary artery catheter with CCO and arterial line with FloTrac
- Patients who are Research Opt-Out
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Cardiac surgery patients
The study uses a within-patient repeated-measures design, where each patient serves as their own control across the three timepoints. The following measures will be recorded:
|
The SpHb monitor is an FDA approved device being used according to its approved indications.
No additional invasive procedures, blood draws, or interventions are performed for research purposes.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Agreement Between SpHb-Based and Pulmonary Artery Catheter Oxygen Delivery Index
大体时间:Three intraoperative timepoints during cardiac surgery: baseline, post-heparin, and post-protamine
|
Bias and 95% limits of agreement between monitor-derived DO₂i (calculated from continuous SpHb and FloTrac cardiac index) and pulmonary artery catheter DO₂i (calculated from arterial blood gas hemoglobin and Swan-Ganz cardiac index), analyzed using Bland-Altman method with mixed-effects modeling to account for repeated measures.
Agreement is considered acceptable if percentage error is <30%.
|
Three intraoperative timepoints during cardiac surgery: baseline, post-heparin, and post-protamine
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Directional Agreement for Changes in Oxygen Delivery Index
大体时间:Changes between consecutive intraoperative timepoints (baseline to post-heparin, post- heparin to post-protamine) during cardiac surgery
|
Four-quadrant concordance rate (with 15% exclusion zone) for directional changes in DO₂i between consecutive timepoints.
Concordance is defined as agreement in direction of change (increase vs decrease) between monitor-derived and gold-standard DO₂i measurements.
Scores range from 0- 100%, with higher percentages indicating better directional agreement.
|
Changes between consecutive intraoperative timepoints (baseline to post-heparin, post- heparin to post-protamine) during cardiac surgery
|
|
Correlation Between Oxygen Delivery Index and Arterial Lactate
大体时间:Three intraoperative timepoints during cardiac surgery: baseline, post-heparin, and post- protamine
|
Pearson or Spearman correlation coefficient between DO₂i (both monitor-derived and gold- standard) and simultaneously measured arterial lactate concentration.
Correlation coefficients range from -1 to +1, with negative values indicating inverse relationship between DO₂i and lactate.
|
Three intraoperative timepoints during cardiac surgery: baseline, post-heparin, and post- protamine
|
|
Agreement Between FloTrac and Swan-Ganz Cardiac Index
大体时间:Three intraoperative timepoints during cardiac surgery: baseline, post-heparin, and post- protamine
|
Percentage error between FloTrac arterial pressure-based cardiac index and Swan-Ganz thermodilution continuous cardiac index.
Percentage error is calculated as (1.96 × SD of differences) / mean cardiac index × 100%.
Agreement is considered acceptable if percentage error is <30%.
|
Three intraoperative timepoints during cardiac surgery: baseline, post-heparin, and post- protamine
|
|
Impact of Baseline SpHb Calibration on Agreement
大体时间:Three intraoperative timepoints during cardiac surgery: baseline, post-heparin, and post- protamine
|
Comparison of limits of agreement before and after in vivo SpHb calibration (baseline- adjusted SpHb using first arterial blood gas hemoglobin value as reference).
Measured as change in bias and 95% limits of agreement between uncalibrated and baseline-calibrated SpHb-based DO₂i compared to gold standard.
|
Three intraoperative timepoints during cardiac surgery: baseline, post-heparin, and post- protamine
|
|
SpHb Signal Usability Rate
大体时间:Three intraoperative timepoints during cardiac surgery: baseline, post-heparin, and post- protamine
|
Percentage of planned timepoints with valid SpHb signal defined by perfusion index (PI) ≥ 0.5.
Scores range from 0-100%, with 100% indicating valid signal at all timepoints.
|
Three intraoperative timepoints during cardiac surgery: baseline, post-heparin, and post- protamine
|
|
Perfusion Index Threshold for Acceptable SpHb Accuracy
大体时间:Three intraoperative timepoints during cardiac surgery: baseline, post-heparin, and post- protamine
|
Minimum perfusion index value associated with acceptable SpHb accuracy, defined as SpHb bias within ±1 g/dL of arterial blood gas hemoglobin.
Perfusion index values range from 0-20%, with higher values indicating better peripheral perfusion.
|
Three intraoperative timepoints during cardiac surgery: baseline, post-heparin, and post- protamine
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Major Adverse Cardiac Events (Exploratory)
大体时间:Within 30 days of surgery
|
Composite endpoint including all-cause mortality, myocardial infarction (elevated troponin with ECG changes or clinical symptoms), stroke (new neurologic deficit with imaging confirmation), or urgent revascularization.
|
Within 30 days of surgery
|
|
Acute Kidney Injury (Exploratory)
大体时间:Within 30 days of surgery
|
AKI defined and staged using KDIGO criteria based on postoperative serum creatinine changes: Stage 1 (1.5-1.9×
baseline or ≥0.3 mg/dL increase), Stage 2 (2.0-2.9×
baseline), Stage 3 (≥3× baseline or ≥4.0 mg/dL or initiation of renal replacement therapy).
|
Within 30 days of surgery
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Benjamin Gorbaty, MD、University of Minnesota
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年10月15日
初级完成 (估计的)
2027年8月1日
研究完成 (估计的)
2027年8月1日
研究注册日期
首次提交
2026年4月30日
首先提交符合 QC 标准的
2026年4月30日
首次发布 (实际的)
2026年5月7日
研究记录更新
最后更新发布 (实际的)
2026年8月18日
上次提交的符合 QC 标准的更新
2026年8月17日
最后验证
2026年8月1日
更多信息
与本研究相关的术语
其他研究编号
- ANES-2026-34768
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
是的
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.